Sheaffer Karyn L, Elliott Ellen N, Kaestner Klaus H
Department of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Cancer Prev Res (Phila). 2016 Jul;9(7):534-46. doi: 10.1158/1940-6207.CAPR-15-0349. Epub 2016 Feb 16.
Intestinal cancer is a heterogeneous disease driven by genetic mutations and epigenetic changes. Approximately 80% of sporadic colorectal cancers are initiated by mutation and inactivation of the adenomatous polyposis coli (APC) gene, which results in unrestrained intestinal epithelial growth and formation of adenomas. Aberrant DNA methylation promotes cancer progression by the inactivation of tumor suppressor genes via promoter methylation. In addition, global DNA hypomethylation is often seen before the formation of adenomas, suggesting that it contributes to neoplastic transformation. Previous studies employed mice with a hypomorphic mutation in DNA methyltransferase 1 (Dnmt1), which exhibited constitutive global DNA hypomethylation and decreased tumorigenesis in the Apc(Min/+) mouse model of intestinal cancer. However, the consequences of intestinal epithelial-specific acute hypomethylation during Apc(Min/+) tumor initiation have not been reported. Using temporally controlled intestinal epithelial-specific gene ablation, we show that total loss of Dnmt1 in the Apc(Min/+) mouse model of intestinal cancer causes accelerated adenoma initiation. Deletion of Dnmt1 precipitates an acute response characterized by hypomethylation of repetitive elements and genomic instability, which surprisingly is followed by remethylation with time. Two months post-Dnmt1 ablation, mice display increased macroadenoma load, consistent with a role for Dnmt1 and DNA methylation in maintaining genomic stability. These data suggest that DNA hypomethylation plays a previously unappreciated role in intestinal adenoma initiation. Cancer Prev Res; 9(7); 534-46. ©2016 AACRSee related article by Lee and Laird, p. 509.
肠道癌是一种由基因突变和表观遗传变化驱动的异质性疾病。大约80%的散发性结直肠癌是由腺瘤性息肉病 coli(APC)基因的突变和失活引发的,这导致肠道上皮细胞不受控制地生长并形成腺瘤。异常的DNA甲基化通过启动子甲基化使肿瘤抑制基因失活来促进癌症进展。此外,在腺瘤形成之前常常会出现全基因组DNA低甲基化,这表明它有助于肿瘤转化。先前的研究使用了DNA甲基转移酶1(Dnmt1)发生低表达突变的小鼠,这些小鼠在肠道癌的Apc(Min/+)小鼠模型中表现出持续性全基因组DNA低甲基化且肿瘤发生减少。然而,在Apc(Min/+)肿瘤起始过程中肠道上皮特异性急性低甲基化的后果尚未见报道。通过时间控制的肠道上皮特异性基因敲除,我们发现肠道癌的Apc(Min/+)小鼠模型中Dnmt1的完全缺失会导致腺瘤起始加速。Dnmt1的缺失引发了一种急性反应,其特征是重复元件低甲基化和基因组不稳定,令人惊讶的是,随后会随着时间重新甲基化。Dnmt1敲除两个月后,小鼠的大腺瘤负荷增加,这与Dnmt1和DNA甲基化在维持基因组稳定性中的作用一致。这些数据表明DNA低甲基化在肠道腺瘤起始中发挥了先前未被认识到的作用。《癌症预防研究》;9(7);534 - 46。©2016美国癌症研究协会。见Lee和Laird的相关文章,第509页。